Related Experiment Video
Updated: Jul 3, 2026
Assay Development for High-Throughput Drug Screening Against Mycobacteria
Published on: October 25, 2024
Comparative anti-gonococcal activity of S-565, a new rifamycin
J M Hamilton-Miller1, T Bruzzese, A Nonis
1Department of Medical Microbiology, Royal Free Hospital School of Medicine, Pond St., London NW3 2QG, UK.
Abstract:
The in vitro activity of S-565, a semi-synthetic rifamycin chemically related to rifampicin but with a longer half-life, has been compared with that of rifampicin, ciprofloxacin, spectinomycin, azithromycin and amoxycillin against Neisseria gonorrhoeae. Modal MICs against 20 strains were 0.13 mg/l for rifampicin and 0.5 mg/l for S-565. There was cross-resistance between the two rifamycins, and each selected for resistance at similar rates. In a time-kill study, S-565 was more rapidly bactericidal than rifampicin at x 1 and x 2 MIC.
More Related Videos
09:57System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
Published on: April 5, 2017
13:47Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
Published on: May 19, 2020
